Related Experiment Video
Updated: Jan 10, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
The ENGAGE Study: A Randomized Trial Optimizing Uptake of Germline Cancer Genetic Services in Childhood Cancer
Background:
Identifying childhood cancer survivors who are already at high risk of subsequent neoplasms and may also have an inherited genetic susceptibility is essential for effective surveillance and prevention. This trial evaluated the effectiveness of remote, centralized telehealth genetic services in increasing service uptake.
Methods:
Childhood Cancer Survivor Study (CCSS) participants at the St. Jude Research Hospital, who were > 18 years old and survivors of a CNS tumor, sarcoma, or more than one primary cancer, were recruited for the study. After completing a baseline survey, participants were randomly assigned to one of three arms: remote telehealth genetic services via phone, videoconference, or usual care. Uptake of genetic services was obtained through study records and the six-month Status Survey.
Findings:
Of the 391 participants recruited, 262 were assigned to remote telehealth services (via phone or videoconference) and 129 to usual care. At six months, 43% (113/262) of participants in remote telehealth services received genetic services compared to 15% (19/129) in the usual care group (OR = 4·4, 95% CI 2·5-8·0, p<0·0001). Uptake of genetic counseling (42% vs. 15%, p < 0·0001) and genetic testing (19% vs. 9%, p = 0·020) were higher in remote telehealth services. Factors associated with higher uptake included not having high-deductible health insurance (OR = 1·67, 95%CI 1·00-2·91, p = 0·049) and lower perceived cost of testing (OR = 1·51, 95%CI 1·17-1·96, p = 0·0014). Top barriers included experiencing higher levels of depression (OR=0·91, 95%CI 0·85-0·98, p = 0·0067) and anxiety (OR=0·93, 95%CI 0·87-1·00, p = 0·036).
Interpretation:
Remote telehealth genetic services improve genetic counseling and testing uptake in childhood cancer. Addressing remaining barriers could maximize their impact and ensure equitable access for childhood cancer survivors and their families.
Funding:
National Cancer Institute (R01-CA237369, U24-CA55727).
Clinical Trial Registration:
NCT04455698 at http://www.ClinicalTrials.gov.
More Related Videos
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
06:53Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Related Concept Videos
Cancer Survival Analysis
Cancer Prevention
Some...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...